Cardiogenic shock remains a significant issue and affects 5% to 10% of patients admitted with an AMI. Mortality remains high despite advances in treatment for AMI. These patients are best treated in centers where they can receive treatment that follows the joint guidelines recommended by ACC and AHA. Rapid reperfusion therapy as well as pharmacologic and mechanical circulatory support provide the best options for survival.